SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells

Recurrent mutations in the splicing factor SRSF2 are associated with poor clinical outcomes in myelodysplastic syndromes (MDS). Their high frequency suggests these mutations drive oncogenesis, yet the molecular explanation for this process is unclear. SRSF2 mutations could directly affect pre-mRNA s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yang, Tebaldi, Toma, Rejeski, Kai, Joshi, Poorval, Stefani, Giovanni, Taylor, Ashley, Song, Yuanbin, Vasic, Radovan, Maziarz, Jamie, Balasubramanian, Kunthavai, Ardasheva, Anastasia, Ding, Alicia, Quattrone, Alessandro, Halene, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274620/
https://www.ncbi.nlm.nih.gov/pubmed/29858584
http://dx.doi.org/10.1038/s41375-018-0152-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274620/
https://www.ncbi.nlm.nih.gov/pubmed/29858584
http://dx.doi.org/10.1038/s41375-018-0152-7

Ejemplares similares